Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | RPA1 | P27694 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MARS1 | P56192 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975817 | 0.88 | ALDH1A1 (0.72) | KMT2AMEN1ALDH1A1PPP1CAKDM4E | |
| SCHEMBL28287989 | 0.87 | ALDH1A1 (0.76) | KMT2AMEN1ALDH1A1ATMPPP1CA | |
| SCHEMBL30882662 | 0.87 | CNR1 (0.52) | KMT2AMEN1ALDH1A1ATMPPP1CA | |
| SCHEMBL30882442 | 0.83 | CHRNA7 (0.55) | KMT2AMEN1ALDH1A1ATMLDHA | |
| SCHEMBL30882521 | 0.82 | CNR1 (0.48) | KMT2AMEN1ALDH1A1ATMPPP1CA | |
| SCHEMBL4097251 | 0.81 | RPA1 (0.60) | ALDH1A1PPP1CARPA1SMN1; SMN2 | |
| SCHEMBL30882605 | 0.79 | CNR1 (0.46) | KMT2AMEN1ALDH1A1ATMLDHA | |
| SCHEMBL6052280 | 0.78 | KMT2A (0.66) | KMT2AMEN1ALDH1A1ATMPPP1CA | |
| SCHEMBL6052304 | 0.78 | KMT2A (0.62) | KMT2AMEN1ALDH1A1ATMPPP1CA | |
| SCHEMBL1764955 | 0.75 | KMT2A (0.73) | KMT2AMEN1ATMPPP1CARPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969925-B | Heteroaryl-triazole compounds | BAYER AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| US-20250066332-A1 | NOVEL HETEROARYL-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-27 | — | — | US | disclosed |
| US-12187705-B2 | Heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-07 | — | — | US | disclosed |
| CN-117903077-B | Dihydrooxadiazinone compound and application thereof | 上海超阳药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117903077-A | Dihydrooxadiazinon compound and application thereof | 上海超阳药业有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116969925-A | Heteroaryl-triazole compounds | 拜耳公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116925043-A | Heteroaryl-triazole compounds | 拜耳公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3904349-B1 | N-(CYCLOPROPYLMETHYL)-5-(METHYLSULFONYL)-N-{1-[1-(PYRIMIDIN-2-YL)-1H-1,2,4-TRIAZOL-5-YL]ETHYL}HETEROCYCLYL AMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS PESTICIDES | BAYER AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-3904350-B1 | N-(CYCLOPROPYLMETHYL)-5-(METHYLSULFONYL)-N-{1-[1-(PYRIMIDIN-2-YL)-1H-1,2,4-TRIAZOL-5-YL]ETHYL}BENZAMIDE DERIVATIVES AND THE CORRESPONDING PYRIDINE-CARBOXAMIDE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-3774778-B1 | N-(CYCLOPROPYLMETHYL)-5-(METHYLSULFONYL)-N-{1-[1-(PYRIMIDIN-2-YL)-1H-1,2,4-TRIAZOL-5-YL]ETHYL}BENZAMIDE DERIVATIVES AND THE CORRESPONDING PYRIDINE-CARBOXAMIDE DERIVATIVES AS PESTICIDES | BAYER AG (DE) | 2023-01-18 | — | — | EP | disclosed |
| CN-101277963-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTIS PHARMACEUTICALS INC (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-101277965-A | Imidazo [2, 1-b ] thiazole derivatives as SIRTUIN modulating compounds | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-01 | — | — | CN | disclosed |
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | KMT2A 402/4885MEN1 2936/4885ALDH1A1 1700/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | KMT2A 137/4885MEN1 3453/4885ALDH1A1 844/4885 |
| US-12187705-B2 | Heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides | CYP4F3, TARS2, H1-3 | KMT2A 1333/4885MEN1 3655/4885ALDH1A1 4008/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | KMT2A 417/4885MEN1 2548/4885ALDH1A1 1903/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | KMT2A 761/4885MEN1 3085/4885ALDH1A1 1331/4885 |
| US-20250066332-A1 | NOVEL HETEROARYL-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS AS PESTICIDES | CYP4F3, TARS2, H1-3 | KMT2A 1530/4885MEN1 3758/4885ALDH1A1 4004/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | KMT2A 761/4885MEN1 3085/4885ALDH1A1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.